Citadel Advisors’s Provention Bio PRVB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-520,560
Closed -$12.5M – 15738
2023
Q1
$12.5M Buy
520,560
+477,796
+1,117% +$6M ﹤0.01% 2504
2022
Q4
$452K Sell
42,764
-191,162
-82% -$1.54M ﹤0.01% 8460
2022
Q3
$1.05M Buy
233,926
+87,503
+60% +$399K ﹤0.01% 6880
2022
Q2
$586K Buy
146,423
+98,892
+208% +$469K ﹤0.01% 8289
2022
Q1
$348K Sell
47,531
-115,805
-71% -$693K ﹤0.01% 10254
2021
Q4
$918K Buy
163,336
+22,121
+16% +$140K ﹤0.01% 8161
2021
Q3
$904K Sell
141,215
-32,499
-19% -$209K ﹤0.01% 8419
2021
Q2
$1.46M Buy
173,714
+21,807
+14% +$176K ﹤0.01% 7375
2021
Q1
$1.59M Buy
151,907
+121,012
+392% +$1.7M ﹤0.01% 6951
2020
Q4
$523K Sell
30,895
-31,179
-50% -$467K ﹤0.01% 8071
2020
Q3
$796K Buy
62,074
+29,645
+91% +$374K ﹤0.01% 6434
2020
Q2
$458K Buy
+32,429
New +$409K ﹤0.01% 7250
2019
Q2
– Sell
-16,864
Closed -$39K – 10074
2019
Q1
$39K Buy
+16,864
New +$39.6K ﹤0.01% 8915

Other funds holding PRVB

Citadel Advisors's PRVB Position: Q2 2023 in Review

Citadel Advisors sold out of Provention Bio (PRVB) in Q2 2023, closing a stake of 520,560 shares — an estimated $12.5M sold.

Citadel Advisors first reported a position in PRVB in Q1 2019 and held it in 13 quarters. The position peaked at $12.5M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

  • Citadel Advisors reported no remaining Provention Bio position as of Q2 2023 after selling out during the quarter.
  • Citadel Advisors sold 520,560 Provention Bio shares in Q2 2023, an estimated $12.5M.
  • Citadel Advisors first reported a position in Provention Bio in Q1 2019 and held it in 13 quarters.
  • Citadel Advisors's Provention Bio position peaked at $12.5M in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Provention Bio as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.